Deals
Novo Nordisk to Add RNA Tech With $3.3 Billion Dicerna Deal
- Novo’s $38.25 a share offer is 80% above target’s last price
- Companies have worked together on projects since 2019
Medications on the shelves inside Hodgson Pharmacy in Longfield, Kent, U.K., on Tuesday, Feb. 5, 2019.
Photographer: Simon Dawson/BloombergThis article is for subscribers only.
Novo Nordisk A/S agreed to buy U.S.-based biotech Dicerna Pharmaceuticals Inc. in a $3.3 billion bid to gain RNA technology that promises to yield new medicines.
Denmark’s Novo will pay $38.25 per share in cash, a premium of 80% to Dicerna’s closing price on Nov. 17, the company said Thursday in a statement. Both boards backed the transaction.